The Tea in STEM

Dark History of Clinical Trials Part 6

12 min · 25 de ago de 2025
Portada del episodio Dark History of Clinical Trials Part 6

Descripción

In this episode, we dive into a chilling case where a promising T-cell therapy showed remarkable results in adolescents and pediatric patients — but when tested in adults, the outcome was tragically different. Phase 1 looked fine, Phase 2 turned deadly. To this day, we still don’t fully understand why. Was it biology? Trial design? Or something deeper about the risks of pushing boundaries in science? Join us as we unpack what went wrong, and what this story teaches us about the fragile line between breakthrough and disaster in clinical research.

Comentarios

0

Sé la primera persona en comentar

¡Regístrate ahora y únete a la comunidad de The Tea in STEM!

Prueba gratis

Empieza 7 días de prueba

$99 / mes después de la prueba. · Cancela cuando quieras.

  • Podcasts solo en Podimo
  • 20 horas de audiolibros al mes
  • Podcast gratuitos

Todos los episodios

49 episodios

episode Dark History of Clinical Trials Part 5 artwork

Dark History of Clinical Trials Part 5

In this powerful installment of Dark History of Clinical Trials, we examine one of the most tragic and transformative episodes in pharmaceutical history: the thalidomide disaster. Marketed as a safe sedative and morning sickness treatment in the late 1950s, thalidomide was distributed to thousands—only to cause severe congenital deformities and pregnancy losses across the globe. This catastrophe exposed critical flaws in drug testing, marketing, and approval processes. In this episode, we uncover: * The rise and reckless distribution of thalidomide * The real human cost behind corporate and regulatory failures * How this tragedy reshaped modern drug approval laws * The birth of the FDA’s MedWatch program and tighter safety controls * Why we now distinguish between OTC and controlled medications Understanding this dark chapter is key to appreciating the safeguards we often take for granted today.

30 de jun de 20259 min